Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 11/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 5/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ARNT | P27540 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344824 | 0.91 | CYP3A4 (0.48) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 | |
| SCHEMBL12132260 | 0.89 | CYP3A4 (0.51) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 | |
| SCHEMBL1344317 | 0.88 | KCNH2 (0.47) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 | |
| SCHEMBL3027563 | 0.86 | CYP3A4 (0.50) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 | |
| SCHEMBL3022832 | 0.85 | CYP3A4 (0.56) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 | |
| SCHEMBL27862294 | 0.84 | CYP3A4 (0.47) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 | |
| SCHEMBL3028160 | 0.84 | CYP3A4 (0.46) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 | |
| SCHEMBL3022988 | 0.84 | CYP3A4 (0.46) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 | |
| SCHEMBL3634456 | 0.84 | KCNH2 (0.44) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 | |
| SCHEMBL13492189 | 0.84 | CYP3A4 (0.58) | CYP3A4KCNH2EPAS1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134711-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080293664-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008122534-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293664-A1 | Non-nucleoside reverse transcriptase inhibitors | XDH, REV1, RTF1 | CYP3A4 979/4885KCNH2 4020/4885EPAS1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.